157 related articles for article (PubMed ID: 33121412)
1. The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection.
Kobak S
Curr Rheumatol Rev; 2021; 17(2):141-152. PubMed ID: 33121412
[TBL] [Abstract][Full Text] [Related]
2. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells.
Hafezi B; Chan L; Knapp JP; Karimi N; Alizadeh K; Mehrani Y; Bridle BW; Karimi K
Cells; 2021 Jul; 10(7):. PubMed ID: 34359931
[TBL] [Abstract][Full Text] [Related]
3. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
Shawki MA; Elsayed NS; Mantawy EM; Said RS
Immunopharmacol Immunotoxicol; 2021 Aug; 43(4):395-409. PubMed ID: 34057871
[TBL] [Abstract][Full Text] [Related]
4. AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm.
Gangemi S; Tonacci A
Cytokine Growth Factor Rev; 2021 Apr; 58():111-113. PubMed ID: 32938545
[TBL] [Abstract][Full Text] [Related]
5. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.
Soy M; Keser G; Atagündüz P; Tabak F; Atagündüz I; Kayhan S
Clin Rheumatol; 2020 Jul; 39(7):2085-2094. PubMed ID: 32474885
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 and inflammatory bowel disease: A pathophysiological assessment.
Yang C; Xiao SY
Biomed Pharmacother; 2021 Mar; 135():111233. PubMed ID: 33433350
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Storm: The Primary Determinant for the Pathophysiological Evolution of COVID-19 Deterioration.
Chen R; Lan Z; Ye J; Pang L; Liu Y; Wu W; Qin X; Guo Y; Zhang P
Front Immunol; 2021; 12():589095. PubMed ID: 33995341
[TBL] [Abstract][Full Text] [Related]
8.
Mardi A; Meidaninikjeh S; Nikfarjam S; Majidi Zolbanin N; Jafari R
Viral Immunol; 2021 Dec; 34(10):679-688. PubMed ID: 34882013
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants.
Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T
Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303
[TBL] [Abstract][Full Text] [Related]
10. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
11. Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation.
Tufan A; Matucci-Cerinic M
Turk J Med Sci; 2021 Dec; 51(SI-1):3391-3404. PubMed ID: 34844296
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19.
Ricciotti E; Laudanski K; FitzGerald GA
Adv Biol Regul; 2021 Aug; 81():100818. PubMed ID: 34303107
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies.
Elemam NM; Maghazachi AA; Hannawi S
Curr Med Res Opin; 2021 Jun; 37(6):929-938. PubMed ID: 33754931
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
Bahari Z; Jangravi Z; Ghoshooni H; Afarinesh MR; Meftahi GH
Inflamm Res; 2021 Apr; 70(4):389-405. PubMed ID: 33608746
[TBL] [Abstract][Full Text] [Related]
16. Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Cure E; Kucuk A; Cure MC
Indian J Pharmacol; 2021; 53(3):226-228. PubMed ID: 34169908
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2.
Cheon SY; Koo BN
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360684
[TBL] [Abstract][Full Text] [Related]
19. Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.
Al-Kuraishy HM; Al-Gareeb AI; Mostafa-Hedeab G; Kasozi KI; Zirintunda G; Aslam A; Allahyani M; Welburn SC; Batiha GE
Front Immunol; 2021; 12():749291. PubMed ID: 34867978
[TBL] [Abstract][Full Text] [Related]
20. Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
Kabeerdoss J; Danda D
Int J Rheum Dis; 2020 Aug; 23(8):998-1008. PubMed ID: 32779341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
